Sun Pharmaceutical subsidiary granted USFDA approval for generic Namenda tablets

Download PDF Copy

May 7 2010

Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE:SUNPHARMA, BSE: 524715) announced that USFDA has granted its subsidiary an approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Forest Laboratories, Inc.'s Namenda 5 mg and 10 mg tablets.

Sun was amongst the first ANDA applicants to submit a substantially complete ANDA with a paragraph IV certification to the '703 patent. Sun's subsidiary is eligible for 180 days generic exclusivity.

These generic Memantine tablets are equivalent to Forest Laboratories, Inc's Namenda® tablets and include two strengths: 5 mg and 10 mg. These strengths of Memantine have a combined annual sale of approximately $1.2 billion in the US.

Memantine tablets are indicated for the treatment of moderate to severe Alzheimer's Disease.

Namenda ® is a registered trademark of Forest Laboratories, Inc.

Licensed from Merz Pharmaceuticals GMBH.

Source:

Sun Pharmaceutical Industries Ltd.

Posted in: Medical Condition News | Pharmaceutical News

Comments (0)

Download PDF Copy

Suggested Reading

University of Maine team develops sustainable method to cut drug production costs

Mass General Brigham study shows US obesity could jump from 40% to 70%

‘Sick to my stomach’: Trump distorts facts on autism, tylenol, and vaccines, scientists say

Study sheds light on how inadequate sleep in teens can contribute to cycles of violence

Mentavi study validates first fully digital diagnostic pathway for adult ADHD

Global cancer cases and deaths expected to soar by 2050 despite advances in treatment

How IoT, AI, and mobile technologies are transforming manufacturing and R&D

Mushrooms deliver nutrition medicine and sustainability solutions in one package

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

(Logout)

Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.